Nanthealth LLC (NYSE:NH) traded down 3% during trading on Friday . The company traded as low as $13.30 and last traded at $13.57, with a volume of 55,941 shares traded. The stock had previously closed at $13.99.

A number of equities research analysts recently commented on the company. Cowen and Company assumed coverage on Nanthealth in a research report on Monday, June 27th. They issued an “outperform” rating and a $19.00 target price on the stock. FBR & Co started coverage on Nanthealth in a research note on Monday, June 27th. They set an “outperform” rating and a $18.00 price objective on the stock. First Analysis started coverage on Nanthealth in a research note on Monday, June 27th. They set an “overweight” rating and a $18.00 price objective on the stock. Jefferies Group started coverage on Nanthealth in a research note on Monday, June 27th. They set a “buy” rating on the stock. Finally, Canaccord Genuity started coverage on Nanthealth in a research note on Monday, June 27th. They set a “buy” rating and a $17.00 price objective on the stock. Five analysts have rated the stock with a buy rating, The stock currently has a consensus rating of “Buy” and an average target price of $18.00.

The firm has a 50 day moving average of $13.88 and a 200 day moving average of $13.88. The company’s market cap is $7.61 billion.

In related news, CEO Patrick Soon-Shiong purchased 357,143 shares of the firm’s stock in a transaction that occurred on Tuesday, June 7th. The shares were purchased at an average cost of $14.00 per share, with a total value of $5,000,002.00. The acquisition was disclosed in a document filed with the SEC, which is available at this link. Also, major shareholder Healthcare Solution Allscripts purchased 714,286 shares of the firm’s stock in a transaction that occurred on Tuesday, June 7th. The stock was bought at an average cost of $14.00 per share, for a total transaction of $10,000,004.00. Following the completion of the purchase, the insider now directly owns 15,000,000 shares in the company, valued at approximately $210,000,000. The disclosure for this purchase can be found here.

Nant Health, LLC is an evidence-based, personalized healthcare company. The Company’s systems-based approach to personalized healthcare applies diagnostics tailored to the specific molecular profiles of patient tissues and integrates this molecular data in a clinical setting with real-time biometric signal and phenotypic data to track patient outcomes and deliver medicine.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.